Soukup T, Morbi A, Lamb BW, et al. A measure of case complexity for streamlining workflow in multidisciplinary tumor boards: Mixed methods development and early validation of the MeDiC tool. Cancer Med. 2020;9:5143--5154. 10.1002/cam4.3026

Nick Sevdalis and James S. A. Green have contributed equally and share the senior author position on this paper.

**Funding information**

United Kingdom\'s National Institute for Health Research (NIHR); NIHR Applied Research Collaboration (ARC) South London; King's Health Partners; Guy's and St Thomas' Charity; Maudsley Charity.

1. INTRODUCTION {#cam43026-sec-0005}
===============

A multidisciplinary approach to cancer diagnosis and treatment appears to be the most effective means of addressing the complex needs of patients with cancer.[^1^](#cam43026-bib-0001){ref-type="ref"}, [^2^](#cam43026-bib-0002){ref-type="ref"}, [^3^](#cam43026-bib-0003){ref-type="ref"}, [^4^](#cam43026-bib-0004){ref-type="ref"}, [^5^](#cam43026-bib-0005){ref-type="ref"} In fact, since 1995, the United Kingdom\'s (UK) National Institute for Health and Care Excellence[^4^](#cam43026-bib-0004){ref-type="ref"} proposed every newly diagnosed cancer case to be discussed in a weekly multidisciplinary tumor board meeting (MTB; also known as cancer multidisciplinary team meeting or MDT in the UK) to improve consistency and quality of cancer care. These meetings enable a range of specialists the opportunity to review each cancer patient\'s case (eg, history, imaging, comorbidities, and psychosocial issues), and contribute their expert input into the formulation of treatment plans, thus optimizing care and improving patient outcomes.[^1^](#cam43026-bib-0001){ref-type="ref"}, [^2^](#cam43026-bib-0002){ref-type="ref"}, [^3^](#cam43026-bib-0003){ref-type="ref"}, [^4^](#cam43026-bib-0004){ref-type="ref"}, [^5^](#cam43026-bib-0005){ref-type="ref"}

However, under pressure from increasing cancer incidence,[^6^](#cam43026-bib-0006){ref-type="ref"}, [^7^](#cam43026-bib-0007){ref-type="ref"} an aging population, financial strains on the healthcare system,[^8^](#cam43026-bib-0008){ref-type="ref"} and specialist shortages,[^9^](#cam43026-bib-0009){ref-type="ref"} more and more patients need to be reviewed by MTBs leaving shorter discussion times and raising quality and safety concerns.[^10^](#cam43026-bib-0010){ref-type="ref"} Moreover, cancer provider time[^11^](#cam43026-bib-0011){ref-type="ref"}, [^12^](#cam43026-bib-0012){ref-type="ref"} and extensive preparation by radiologists and pathologists[^13^](#cam43026-bib-0013){ref-type="ref"} is hugely expensive, inadvertently exacerbating financial pressures.[^11^](#cam43026-bib-0011){ref-type="ref"}, [^12^](#cam43026-bib-0012){ref-type="ref"}, [^13^](#cam43026-bib-0013){ref-type="ref"} To address these concerns, both Cancer Research UK,[^10^](#cam43026-bib-0010){ref-type="ref"} the UK National Cancer Advisory Group,[^5^](#cam43026-bib-0005){ref-type="ref"} and the NHS England and NHS Improvement[^14^](#cam43026-bib-0014){ref-type="ref"} recently highlighted prioritization of complex cancer cases as an important safety and quality improvement strategy for MTBs. This is in‐line with implementation of MTBs in the United States, where typically the most complex (ie, not all) patients are reviewed by a MTB to plan their care.[^15^](#cam43026-bib-0015){ref-type="ref"} Furthermore, clinicians report case complexity as a key determinant of inconsistent MTB decision‐making.[^16^](#cam43026-bib-0016){ref-type="ref"}

Yet, what constitutes a "complex" cancer case and factors contributing to case complexity remain unclear.[^14^](#cam43026-bib-0014){ref-type="ref"} Clinically, case complexity might refer to specific patient characteristics (eg, prior surgery) or cancer features that lead to prolonged MTB review that makes formulating a treatment plan challenging.[^5^](#cam43026-bib-0005){ref-type="ref"}, [^10^](#cam43026-bib-0010){ref-type="ref"}, [^16^](#cam43026-bib-0016){ref-type="ref"} From a health policy perspective,[^5^](#cam43026-bib-0005){ref-type="ref"}, [^10^](#cam43026-bib-0010){ref-type="ref"}, [^14^](#cam43026-bib-0014){ref-type="ref"} health systems are encouraged to streamline their MTB processes using validated tools to prioritize cancer case workload, ultimately routing cancer cases efficiently through MTBs based on complexity.[^5^](#cam43026-bib-0005){ref-type="ref"}, [^9^](#cam43026-bib-0009){ref-type="ref"}, [^10^](#cam43026-bib-0010){ref-type="ref"} It thus follows that some way of gauging complexity in a valid and reliable manner is necessary.

This study aims to address this need. We report development and initial validation of an evidence‐based and expert‐derived tool for use by cancer MTBs to safely assess complexity of a cancer patient\'s case and facilitate efficiency in planning treatment---the Measure of case‐Discussion Complexity (MeDiC) tool.

2. METHODS {#cam43026-sec-0006}
==========

2.1. Study design and setting {#cam43026-sec-0007}
-----------------------------

MeDiC was developed over a 30‐month period (May 2014 to November 2016). It was trialed through six rigorous phases and a mixed‐methods approach, including ethnographic interviews and observations, two rounds of national surveys, two rounds of feasibility and reliability testing on video recorded meetings, expert consensus, and multiple expert team reviews (Figure [1](#cam43026-fig-0001){ref-type="fig"}).

![Development of the Measure of Case‐Discussion Complexity (MeDiC) Tool for multidisciplinary tumor board team meetings. Reprinted with permission from Soukup, 2017.[^17^](#cam43026-bib-0017){ref-type="ref"}](CAM4-9-5143-g001){#cam43026-fig-0001}

Data were collected from hospitals across England (Phases 1‐3 and 5‐6) and from the entire UK (Phase 4). Eligibility was defined as MTB members who regularly attend weekly care planning meetings. The research was approved by corresponding local and national institutional review boards prior to data collection.

We summarize the purpose and methods for each phase of the MeDiC tool development and validation below.

2.2. Patient and public involvement {#cam43026-sec-0008}
-----------------------------------

Patient and public were not involved in this study.

2.3. Tool development and validation phases {#cam43026-sec-0009}
-------------------------------------------

### 2.3.1. Phase 1. Exploratory ethnographic interviews and observations: Complexity item identification (May‐November 2014) {#cam43026-sec-0010}

We conducted interviews with cancer specialists to better understand what constitutes a complex case for their MTBs. We selected participants using opportunistic sampling and asked a single open‐ended question: "What factors in your opinion contribute to case‐discussion complexity in MTBs?" We recorded each factor put forward by the interviewees.

### 2.3.2. Phase 2. Content validation survey for case complexity items (November 2014‐December 2015) {#cam43026-sec-0011}

We validated Phase 1 factors with a larger sample of cancer specialists in order to determine whether they adequately represented all facets of complexity. To do so, we compiled the factors into a survey (paper and electronic version). We asked participants to rate each complexity factor on a 1‐5 Likert scale (1 = very simple case, rapid MTB review; 5 = very complex case, in‐depth MTB review). We also asked for additional factors adding to case complexity. We used the National Institute for Health Research\'s Clinical Research Network Portfolio to invite all hospitals with MTBs in England to participate. Hospitals opting into the study distributed the survey to their MTBs through local research support teams.

### 2.3.3. Phase 3. Expert review: Preliminary content validation of complexity items (February 2016) {#cam43026-sec-0012}

We held a 2‐hour virtual conference with expert cancer specialists (BWL & JG: attending urologic cancer surgeons; TG and KH: attending breast oncoplastic surgeons) and an expert in surgical safety and psychometrics (NS). The conference aimed to determine inclusion of factors from Phases 1 and 2 into our tool. A list of complexity factors ranked based on their item‐content validity indices (see below) was provided to the experts allowing them to evaluate the candidate factors. The experts rated each factor as "include," "exclude," or "equivocal." Scoring was done via consensus[^18^](#cam43026-bib-0018){ref-type="ref"}, [^19^](#cam43026-bib-0019){ref-type="ref"}: all four cancer specialists had to agree for an item to be retained.[^20^](#cam43026-bib-0020){ref-type="ref"}, [^21^](#cam43026-bib-0021){ref-type="ref"}

### 2.3.4. Phase 4. National survey: Item weighing and national content validation (March‐June 2016) {#cam43026-sec-0013}

In collaboration with Cancer Research UK (one of the largest cancer support charitable foundations, which funds research, service provision, and workforce development),[^10^](#cam43026-bib-0010){ref-type="ref"} we conducted a national survey. The aim was to determine each individual factor\'s weight in terms of how much each contributes to case complexity; and to further establish content validity of the complexity factors that emerged from Phase 3 expert consensus.

### 2.3.5. Phases 5 and 6. Video recordings of MTBs: feasibility, reliability, and validity testing (September 2015‐November 2016) {#cam43026-sec-0014}

We first assessed the feasibility of scoring the MeDiC tool and reliability between assessors on video‐recorded MTBs. We video recorded 12 weeks of breast, colorectal, and gynecological MTBs, and used the first two boards from each cancer team, respectively, for this phase. We then refined MeDiC by clarifying the wording and scoring anchors (Phase 5). We further assessed the feasibility of scoring the MeDiC items and reliability between assessors on the remaining 30 video‐recorded MTBs (Phase 6).

All cancer cases reviewed at these MTBs were scored by a clinical research fellow (AM) and a research psychologist (TS) with over 5 years of expertise assessing cancer MTBs. This determined feasibility of scoring the individual items for each patient, and the reliability between the two assessors. After an initial training session (to calibrate the assessors), MeDiC factors were separately scored using a checklist principle by each assessor and annotated to provide justification for each assigned score.

We categorized factors to be included into MeDiC into three domains for scoring. For *clinical complexity*, factor weights (as determined by the mean respondent ratings from Phase 4) were added when calculating the overall clinical complexity score. For *logistical problems*, number of occurrences within each patient review was counted, the sum of which constitutes logistical complexity score. We calculated the *overall complexity score* for each patient case by adding up clinical and logistical scores. The scores, as well as the feasibility and usability of the tool were discussed by the assessors over two in‐depth data review sessions.

2.4. Data analyses {#cam43026-sec-0015}
------------------

Our overarching hypothesis was that more complex cancer cases, as scored by MeDiC, would take objectively longer time for the MTB to review and reach a treatment recommendation. We briefly describe our core endpoint analyses (validity, review length, reliability, and complexity level scoring) with full details available in Supplemental File 1.

### 2.4.1. Validity analyses {#cam43026-sec-0016}

We measured content validity of complexity factors included into MeDiC using a widely used measure, the item‐content validity index (I‐CVI).[^20^](#cam43026-bib-0020){ref-type="ref"}, [^21^](#cam43026-bib-0021){ref-type="ref"} This index takes both the expert rating and number of respondents into consideration. We used I‐CVI ranges to guide our selection of complexity factors for retention, revision, or deletion in different phases. We further validated MeDiC using correlations between individual factors and the time spent reviewing a case at the MTB, defined as length of time (minutes:seconds) between start and end of each patient\'s case review. We also used the *overall complexity score* (ie, item‐total correlation). We reported partial correlations controlling for tumor type for continuous variables, and point‐biserial correlations for associations between continuous and dichotomous factors.

### 2.4.2. Reliability analyses {#cam43026-sec-0017}

We assessed reliability between the two MeDiC assessors (AM and TS) using interclass correlation coefficients (ICC) for continuous variables, and Kappa for categorical items, with generally accepted reliability coefficients of 0.70 and above.[^22^](#cam43026-bib-0022){ref-type="ref"} Cronbach\'s alpha was calculated to assess internal consistency. We also applied Cronbach\'s alpha coefficient as a psychometric criterion to determine whether a complexity factor should be removed in the process of tool development.

### 2.4.3. Complexity levels scoring {#cam43026-sec-0018}

We determined complexity levels using percentiles and quartile values as cut‐off points. For validation purposes, we then used Kruskal‐Wallis H and Mann‐Whitney U tests to analyze differences in MTB review time length across different levels of case complexity.

We used bootstrapping with stratified sampling and tumor type as a stratification variable throughout the analyses.[^23^](#cam43026-bib-0023){ref-type="ref"} All analyses were carried out using SPSS^®^ version 20.0 with significance set at *P* \< .05.

3. RESULTS {#cam43026-sec-0019}
==========

In ***Phase 1***, we conducted 15 interviews with cancer specialists from three hospitals in England, including surgeons (n = 7), oncologists (n = 2), cancer nurses (n = 2), physicians (n = 2), radiologists (n = 1), and pathologists (n = 1) across lung, breast, urology, head and neck, and colorectal cancers. These specialists identified 51 complexity factors, which were grouped into four themes: pathology, patient and treatment factors (Table [S2](#cam43026-sup-0001){ref-type="supplementary-material"}).

In ***Phase 2*** *,* we compiled the Phase 1 factors into a survey for cancer specialists. Four National Health Service Trusts in England comprising nine MTBs (breast, brain, lung, colorectal, gestational trophoblastic disease, head and neck, skin, urology, and hem‐oncology) participated. Response rate was 48% (52/108) including oncologists (n = 17), cancer nurses (n = 11), surgeons (n = 8), radiologists (n = 8), physicians (n = 6), and pathologists (n = 2). Nine new complexity factors were suggested by survey respondents; totaling 60 items for potential MeDiC inclusion at this point of the research (Table [S2](#cam43026-sup-0001){ref-type="supplementary-material"}).

In ***Phase 3***, a virtual conference with four surgical oncology and one safety/psychometrics experts was held for content validation using all 60 complexity factors---listed as MeDiC potential items. Out of the initial 60 items, 39 were excluded (ICV‐I \< 0.67) and 21 received full agreement (I‐CVI = 1). It was further recommended by the experts that six items are merged due to shared meaning (ie, cognitive with mental health comorbidities, immunocompromised with significant physical comorbidities, and treatment toxicity and contraindications to standard treatment), and seven are grouped under the logistical issues domain; totaling 10 items for potential MeDiC inclusion at this point of the study (Table [S2](#cam43026-sup-0001){ref-type="supplementary-material"}).

***Phase 4*** incorporated complexity items (N = 10) with full agreement into a national Cancer Research UK survey[^9^](#cam43026-bib-0009){ref-type="ref"} to determine their weight and the level of complexity each factor adds. We received 973 responses (the denominator for the survey is unknown, hence a response rate cannot be computed; the absolute N of respondents was comparable to a recent UK national cancer specialist survey, which had 1141 respondents)[^24^](#cam43026-bib-0025){ref-type="ref"} from surgeons, oncologists, radiologists, pathologists, physicians, and cancer nurses from 10 different cancer specialties, including, breast, urology, lung, colorectal, head and neck, skin, upper gastrointestinal, gynecology, hematology, and brain across Scotland, Northern Ireland, Wales, and England, resulting in full UK coverage. We used mean ratings for each of the 10 complexity factors (items 1‐10 in Table [S3](#cam43026-sup-0001){ref-type="supplementary-material"}) as weights in scoring and determining the overall complexity of cases in subsequent phases 5 and 6. Ten new items were proposed for inclusion by respondents (items 11‐20 in Table [S3](#cam43026-sup-0001){ref-type="supplementary-material"}) and retained for further evaluation with the original items; totaling 20 items for potential MeDiC inclusion at this point of the study.

In ***Phase 5***, we conducted preliminary feasibility assessment of the MeDiC scoring and psychometric analyses on a smaller sample of five video‐recorded MTBs including 81 patient reviews (18 breast, 34 colorectal, and 29 gynecological). We determined I‐CVIs, frequencies, and associations with case review length during the meetings for each patient (Table [S4](#cam43026-sup-0001){ref-type="supplementary-material"}), along with reliability and validity testing (Table [S5](#cam43026-sup-0001){ref-type="supplementary-material"}).

The feasibility testing revealed several issues. Items *poor performance status, mental health comorbidity*, and *socioeconomic issues* did not apply to any cases (see Table [S4](#cam43026-sup-0001){ref-type="supplementary-material"}), meaning their validity was not assessable, warranting further testing on a bigger sample. Similarly, items *guidelines do not account for patients\' situation, treatment failure,* and *lifestyle risks*, applied to only 1case each. Nonetheless, *guidelines do not account for patients\' situation* (02:46 to 05:15 (minutes:seconds) case review duration) and *treatment failure/toxicity and contraindications* (02:46 to 04:09 (minutes:seconds) case review duration) led to a nearly twofold increase in review length by the MTBs, suggesting a potentially good proxy for complexity (see Table [S4](#cam43026-sup-0001){ref-type="supplementary-material"}).

Additionally, feasibility testing revealed that some of the more basic indicators of pathology are not captured in MeDiC, yet these are needed to improve the sensitivity of the tool. Therefore seven new items were added, that is, whether the tumor is a confirmed malignant cancer, whether it is large and has metastasized, whether it is advanced cancer, and has an invasive component, or nodal involvement, and whether there is a residual tumor left either because of incomplete excision or because of an incomplete biological response to treatment (see items 20‐27 in Table [S4](#cam43026-sup-0001){ref-type="supplementary-material"}). Although it may be counterintuitive to have the *malignancy* as a stand‐alone indicator of complexity, we found it a necessary starting point in scoring, especially, since some MTBs also discuss benign or suspicious cases. For example, a case that is malignant but has none of the other variables will be simple or of low complexity in comparison to a case that is not only malignant but also advanced and potentially unresectable, or incompletely excised. Hence it is the combination of different factors that determines overall complexity.

In terms of reliability (Table [S5](#cam43026-sup-0001){ref-type="supplementary-material"}), all cases were double rated by the clinical and nonclinical researchers with ICCs higher than the generally accepted 0.70.[^21^](#cam43026-bib-0022){ref-type="ref"} The Cronbach\'s alpha measuring internal consistency of MeDiC scoring was good at 0.77. Hence 27 complexity items were brought into the final study phase.

Finally, ***Phase 6*** included MeDiC scoring of these 27 items and analysis on a large sample of 30 video‐recorded MTBs, which reviewed and managed 822 patients (241 breast, 185 colorectal, and 396 gynecological).[^25^](#cam43026-bib-0025){ref-type="ref"} Interassessor scoring reliability on a subsample of 136 cases (17% of total) was good with Kappa statistics per item showing a minimum coefficient of 0.53 and maximum of 1.00. Disagreements (n = 15) were due to missing elements of the case review due to recording lapses. Cronbach\'s alpha measuring internal consistency was good at 0.70.

*The final list of MeDiC factors* with their reliability coefficients, frequency counts, and correlation coefficients with, first, total complexity score, and, second, case review duration are shown in Table [1](#cam43026-tbl-0001){ref-type="table"}. We color‐coded items using a "traffic‐light" system for a visual guide to how well they measure complexity: green represents good measure, amber fair, and red poor (the latter are candidates for removal). Our sensitivity analysis across tumors was broadly similar to the data presented in Table [1](#cam43026-tbl-0001){ref-type="table"}, with the exception of five discrepancies detailed in Supplemental File 6.

###### 

Final list of complexity factors used in the second and final phase of feasibility and reliability testing

  No.                                                            Complexity factor                                                                                 Item weighing   Assessor reliability                                  Item reliability                                      Item frequency   Correlation[^e^](#cam43026-note-0008){ref-type="fn"}                                                                                                                                                                                                                                  
  -------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------- ----------------------------------------------------- ----------------------------------------------------- ---------------- ------------------------------------------------------ ----------------------------------------------------- --------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------
  Pathology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  1                                                              Malignancy                                                                                        1               1.000                                                 0.668                                                 433              54                                                     0.57[\*\*](#cam43026-note-0012){ref-type="fn"}        33        .47[\*\*](#cam43026-note-0012){ref-type="fn"}        22                                                   .27[\*\*](#cam43026-note-0012){ref-type="fn"}        7
  2                                                              Invasive component                                                                                1               0.984                                                 0.669                                                 253              31                                                     0.56[\*\*](#cam43026-note-0012){ref-type="fn"}        31        .46[\*\*](#cam43026-note-0012){ref-type="fn"}        21                                                   .23[\*\*](#cam43026-note-0012){ref-type="fn"}        5
  3                                                              Multiple cancers (incl. multiple primaries)                                                       1               1.000                                                 0.688                                                 68               8                                                      0.38[\*\*](#cam43026-note-0012){ref-type="fn"}        14        .32[\*\*](#cam43026-note-0012){ref-type="fn"}        1                                                    .27[\*\*](#cam43026-note-0012){ref-type="fn"}        7
  4                                                              Increased size (T3, T4)                                                                           1               0.974                                                 0.684                                                 80               10                                                     0.42[\*\*](#cam43026-note-0012){ref-type="fn"}        18        .36[\*\*](#cam43026-note-0012){ref-type="fn"}        13                                                   .16[\*\*](#cam43026-note-0012){ref-type="fn"}        3
  5                                                              Nodes affected                                                                                    1               1.000                                                 0.678                                                 103              13                                                     0.49[\*\*](#cam43026-note-0012){ref-type="fn"}        24        .40[\*\*](#cam43026-note-0012){ref-type="fn"}        16                                                   .27[\*\*](#cam43026-note-0012){ref-type="fn"}        7
  6                                                              Mets (local or distant)                                                                           1               1.000                                                 0.667                                                 111              14                                                     0.57[\*\*](#cam43026-note-0012){ref-type="fn"}        33        .51[\*\*](#cam43026-note-0012){ref-type="fn"}        26                                                   .31[\*\*](#cam43026-note-0012){ref-type="fn"}        10
  7                                                              Advanced stage, progressive                                                                       1               1.000                                                 0.676                                                 99               12                                                     0.50[\*\*](#cam43026-note-0012){ref-type="fn"}        25        .42[\*\*](#cam43026-note-0012){ref-type="fn"}        17                                                   .29[\*\*](#cam43026-note-0012){ref-type="fn"}        8
  8                                                              Unusual or rare tumor type                                                                        4               0.953                                                 **0.697**                                             34               4                                                      **0.25** [\*\*](#cam43026-note-0012){ref-type="fn"}   **6**     **.37** [\*\*](#cam43026-note-0012){ref-type="fn"}   **13**                                               **.14** [\*\*](#cam43026-note-0012){ref-type="fn"}   **2**
  9                                                              Residual tumor                                                                                    1               0.881                                                 0.699                                                 47               6                                                      0.21[\*\*](#cam43026-note-0012){ref-type="fn"}        5         .18[\*\*](#cam43026-note-0012){ref-type="fn"}        3                                                    .16[\*\*](#cam43026-note-0012){ref-type="fn"}        3
  10                                                             Recurrence                                                                                        1               1.000                                                 0.694                                                 39               6                                                      0.28[\*\*](#cam43026-note-0012){ref-type="fn"}        8         .27[\*\*](#cam43026-note-0012){ref-type="fn"}        7                                                    .26[\*\*](#cam43026-note-0012){ref-type="fn"}        7
  Patient factors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  11                                                             Previous history of cancer                                                                        1               1.000                                                 **0.697**                                             89               11                                                     **0.30** [\*\*](#cam43026-note-0012){ref-type="fn"}   **9**     **.33** [\*\*](#cam43026-note-0012){ref-type="fn"}   **11**                                               **.14** [\*\*](#cam43026-note-0012){ref-type="fn"}   **2**
  12                                                             Previous oncological treatment                                                                    1               1.000                                                 0.685                                                 46               6                                                      0.41[\*\*](#cam43026-note-0012){ref-type="fn"}        17        .46[\*\*](#cam43026-note-0012){ref-type="fn"}        20                                                   .28[\*\*](#cam43026-note-0012){ref-type="fn"}        8
  13                                                             Significant surgical history                                                                      3               1.000                                                 0.692                                                 83               10                                                     0.34[\*\*](#cam43026-note-0012){ref-type="fn"}        11        .49[\*\*](#cam43026-note-0012){ref-type="fn"}        21                                                   .17[\*\*](#cam43026-note-0012){ref-type="fn"}        3
  14                                                             Significant physical comorbidity (incl. poor PS[^g^](#cam43026-note-0010){ref-type="fn"})         3               0.983                                                 0.696                                                 178              22                                                     0.33[\*\*](#cam43026-note-0012){ref-type="fn"}        11        .50[\*\*](#cam43026-note-0012){ref-type="fn"}        25                                                   .17[\*\*](#cam43026-note-0012){ref-type="fn"}        3
  15                                                             Mental health and cognitive comorbidity                                                           4               1.000                                                 0.700                                                 13               2                                                      0.15[\*\*](#cam43026-note-0012){ref-type="fn"}        2         .26[\*\*](#cam43026-note-0012){ref-type="fn"}        7                                                    .05                                                  0
  16                                                             Socioeconomic issues                                                                              3               1.000                                                 0.701                                                 3                0                                                      0.13[\*\*](#cam43026-note-0012){ref-type="fn"}        2         .14[\*\*](#cam43026-note-0012){ref-type="fn"}        2                                                    .06                                                  0
  17                                                             Patient choice and family opinion[\*](#cam43026-note-0011){ref-type="fn"}                         1               1.000                                                 0.701                                                 62               8                                                      0.23[\*\*](#cam43026-note-0012){ref-type="fn"}        5         .21[\*\*](#cam43026-note-0012){ref-type="fn"}        5                                                    .11[\*\*](#cam43026-note-0012){ref-type="fn"}        1
  18                                                             Lifestyle risks                                                                                   3               1.000                                                 0.702                                                 7                1                                                      0.06                                                  0         .08[\*](#cam43026-note-0011){ref-type="fn"}          1                                                    −.01                                                 0
  Treatment factors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  19                                                             Diagnostic uncertainty and inconclusiveness of diagnostic tests                                   1               0.941                                                 0.693                                                 105              13                                                     0.39[\*\*](#cam43026-note-0012){ref-type="fn"}        16        .34[\*\*](#cam43026-note-0012){ref-type="fn"}        12                                                   .29[\*\*](#cam43026-note-0012){ref-type="fn"}        8
  20                                                             Unusual anatomy/distribution of tumor                                                             1               1.000                                                 0.691                                                 37               5                                                      0.33[\*\*](#cam43026-note-0012){ref-type="fn"}        11        .33[\*\*](#cam43026-note-0012){ref-type="fn"}        11                                                   .24[\*\*](#cam43026-note-0012){ref-type="fn"}        6
  21                                                             Conflict of opinions about treatment options                                                      4               0.905                                                 **0.703**                                             46               6                                                      **0.17** [\*\*](#cam43026-note-0012){ref-type="fn"}   **3**     **.32** [\*\*](#cam43026-note-0012){ref-type="fn"}   **10**                                               **.29** [\*\*](#cam43026-note-0012){ref-type="fn"}   8
  22                                                             Further tests and patient assessment needed                                                       1               1.000                                                 **0.708**                                             231              29                                                     **0.46** [\*\*](#cam43026-note-0012){ref-type="fn"}   **21**    **.27** [\*\*](#cam43026-note-0012){ref-type="fn"}   **7**                                                **.27** [\*\*](#cam43026-note-0012){ref-type="fn"}   **7**
  23                                                             Treatment toxicity and contraindications                                                          3               1.000                                                 0.699                                                 5                0                                                      0.17[\*\*](#cam43026-note-0012){ref-type="fn"}        3         .21[\*\*](#cam43026-note-0012){ref-type="fn"}        4                                                    .09[\*](#cam43026-note-0011){ref-type="fn"}          1
  24                                                             Further input needed from other specialties                                                       1               0.978                                                 0.701                                                 116              14                                                     0.27[\*\*](#cam43026-note-0012){ref-type="fn"}        7         .26[\*\*](#cam43026-note-0012){ref-type="fn"}        7                                                    .18[\*\*](#cam43026-note-0012){ref-type="fn"}        3
  25                                                             Pathway does not account for patients specific situation                                          4               ---                                                   0.702                                                 1                0                                                      0.01                                                  0         .03                                                  0                                                    .02                                                  0
  26                                                             Trial eligibility                                                                                 1               1.000                                                 0.701                                                 3                0                                                      0.10[\*](#cam43026-note-0011){ref-type="fn"}          1         .09[\*](#cam43026-note-0011){ref-type="fn"}          1                                                    .02                                                  0
  27                                                             **Logistical complexity** (occurrences per discussion)[^f^](#cam43026-note-0009){ref-type="fn"}   **---**         **---**                                               **0.953** [^b^](#cam43026-note-0005){ref-type="fn"}   **---**          **42**                                                 **0.19** [\*\*](#cam43026-note-0012){ref-type="fn"}   13        **---**                                              **---**                                              **.34** [\*\*](#cam43026-note-0012){ref-type="fn"}   12
  **Total clinical complexity** (sum of items 1 to 26)           **---**                                                                                           **---**         **0.911** [^b^](#cam43026-note-0005){ref-type="fn"}   **---**                                               **---**          **---**                                                **---**                                               **---**   **---**                                              **.55** [\*\*](#cam43026-note-0012){ref-type="fn"}   30                                                   
  **Total complexity** (sum of clinical and logistical scores)   **---**                                                                                           **---**         **0.879** [^b^](#cam43026-note-0005){ref-type="fn"}   **---**                                               **---**          **0.98** [\*\*](#cam43026-note-0012){ref-type="fn"}    97                                                    **---**                                                        **.59** [\*\*](#cam43026-note-0012){ref-type="fn"}   35                                                   

N = 822 discussions (15 missing cases). Green = good measure of complexity. Yellow = fair. Red = weak and could be removed. Boldface = values changed as a result of item weighing. Percentage values have been rounded to the nearest integer for ease of reading. MeDiC Copyright 2017 ^©^ Soukup Sevdalis Green under CC‐BY‐NC‐ND terms. Reprinted with permission from Soukup, 2017.[^17^](#cam43026-bib-0017){ref-type="ref"}

Cronbach\'s alpha is 0.701.

Interclass correlation coefficient (ICC).

Adjusted for item weighing.

Clinical complexity total.

Point‐biserial correlation coefficients for items 1‐26; Partial correlation controlling for tumor type for discussion time, clinical, logistical, and overall complexity.

*R* between total and logistical complexity is 0.36\*\* (12.6% of total variance explained).

Performance status.

*P *\< .05.

*P* \< .01.
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We further validated MeDiC scores against a practical and objective measure of case complexity: duration of MTB review for each case presented for a management plan to be agreed. To do this analysis, we categorized complexity levels into four groups using three quartile medians with bias‐corrected standard errors and confidence intervals (Table [2](#cam43026-tbl-0002){ref-type="table"}). We then applied the overall complexity levels to individual MTBs. We found the four complexity levels were significantly distinct with gradual increases in mean time spent reviewing each patient (*χ* ^2^(3) = 309.67, *P* \< .001)---which provided further validation that MeDiC truly captures underlying case complexity. As shown in Table [3](#cam43026-tbl-0003){ref-type="table"}, 43% of colorectal cases fell within the top 25% of the data, that is, within the very high complexity range. In contrast, the gynecological MTB had had the smallest frequency of high/very high complexity cases, with low to moderately complex cases most prevalent. The breast cancer team had a more balanced spread of patient complexity. Summary statistics of the entire clinical complexities across participating MTBs as assessed by MeDiC are shown in Table [3](#cam43026-tbl-0003){ref-type="table"}.

###### 

Summary statistics for the total MeDiC score across tumor boards and overall dataset

  Cancer team     N     Mean (SD)   Median (IQR)   Minimum, maximum   Logistical problems   
  --------------- ----- ----------- -------------- ------------------ --------------------- ----
  Breast          241   4 (4)       3 (4)          0, 18              84                    29
  Gynecological   396   3 (4)       2 (3)          0, 26              134                   48
  Colorectal      185   6 (4)       6 (5)          0, 19              121                   23
  Total           822   4 (4)       3 (5)          0, 26              339                   41

SD = standard deviation*.*IQR = interquartile range*.* % is a percentage of observed cases where logistical problems were present. MeDiC total score range is 0--26, with higher scores indicating higher case complexity. Reprinted with permission from Soukup, 2017.[^17^](#cam43026-bib-0017){ref-type="ref"}
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###### 

Complexity levels and mean case review time durations across tumor boards and overall dataset (all tumor boards)

                                       25th percentile   50th percentile   75th percentile   
  ------------------------------------ ----------------- ----------------- ----------------- -----------
  Complexity score:                    ≤1                2‐3               4‐6               ≥7
  Complexity level:                    Low               Moderate          High              Very High
  Breast cancer tumor boards                                                                 
  \% of case reviews                   33%               23%               24%               20%
  Mean review time (MM:SS)             00:52             02:06             02:38             05:06
  Median review time (MM:SS)           00:36             02:03             02:28             04:28
  Range review time (MM:SS)            02:21             03:59             05:13             09:16
  N of case reviews                    79                56                58                48
  Gynecological cancer tumor boards                                                          
  \% of case reviews                   33%               34%               18%               15%
  Mean review time (MM:SS)             01:28             02:11             03:13             04:38
  Median review time (MM:SS)           01:15             02:00             03:00             04:00
  Range review time (MM:SS)            05:09             10:59             07:35             14.10
  N of case reviews                    130               135               72                59
  Colorectal cancer tumor boards                                                             
  \% of case reviews                   8%                20%               30%               43%
  Mean review time (MM:SS)             01:01             02:09             02:34             04:08
  Median review time (MM:SS)           01:11             02:07             02:20             03:17
  Range review time (MM:SS)            02:09             04:44             06:04             13:47
  N of case reviews                    14                37                55                79
  Overall dataset (all tumor boards)                                                         
  \% of case reviews                   27%               28%               23%               23%
  Mean review time (MM:SS)             01:13             02:10             02:50             04:32
  Median review time (MM:SS)           01:06             02:00             02:27             04:05
  Range review time (MM:SS)            05:09             11:02             07:47             14:00
  N of case reviews                    223               228               185               186

Categories are based on quartile median values from overall dataset bootstrapped on 5000 stratified samples with tumor type as a stratification variable. Median (upper and lower bias corrected confidence intervals) for the 25th percentile was 1 (1.14‐1.56), for the 50th percentile was 3 (2.99‐3.46), and for the 75th percentile 6 (5.64‐6.57). In red are values that represent highest scores. Reprinted with permission from Soukup, 2017.[^17^](#cam43026-bib-0017){ref-type="ref"}
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4. DISCUSSION {#cam43026-sec-0020}
=============

To the best of our knowledge, this study offers the first tool to assess the clinical complexity of a cancer patient managed in a tumor board setting. Through a rigorous multiphase research process, with expert input from cancer specialists, we produced the MeDiC tool with evidence of reliability and validity in its scores, feasibility in utilization, and correlation with length of time a case review takes across different MTBs. Our analysis confirmed the hypothesis that the cases that obtain higher MeDiC scores take significantly longer time to discuss and make a treatment plan for within MTBs---thus validating the underlying complexity dimension that MeDiC is intended to capture.

We see numerous ways in which MeDiC can be used by MTBs. In health systems where only a select set of cancer patients are brought to a MTB for review, as is the case in the United States, MeDiC offers a standardized tool to facilitate, standardize, and report how the cases are selected for MTB review. We propose that in such systems, cases could be selected based on complexity---with the cut off determined by individual MTBs. Using MeDiC in this approach would allow less complex cases to be treated according to well‐defined guidelines and evidence‐based protocols agreed on by the entire MTB. While being selective is often the de facto approach used in the United States where institutional cancer accreditation (eg, American College of Surgeons Commission on Cancer)[^28^](#cam43026-bib-0029){ref-type="ref"} might rely on presenting a proportion of cancer patients at a cancer conference, there is typically not a systematic distinction based on case complexity. This could lead institutions to potentially meet the measure but not consistently among those most likely to benefit (ie, complex patients) and without documentation of doing so. These cases could instead be managed through the MTB chair, ratified by team members with quality assurance maintained through specialist review of pathology and radiology investigations, and regular audit of recommended treatment options. This would redistribute the MTB work toward cases with greater clinical need as illustrated in Figure [2](#cam43026-fig-0002){ref-type="fig"}.

![Example of how Measure of case‐Discussion Complexity (MeDiC) could be used to streamline workload](CAM4-9-5143-g002){#cam43026-fig-0002}

Furthermore, in health systems where MTBs are mandatory, for example, in the United Kingdom, current policy discussions reveal concerns regarding the sustainability of such uniform application of MTBs;[^26^](#cam43026-bib-0026){ref-type="ref"} and with the guidance on streamlining published by NHS England,[^14^](#cam43026-bib-0014){ref-type="ref"} the mandate for discussing all cancer cases no longer exists. Clinically, there is the imbalance of more complex patients being squeezed for time due to very long case lists the MTB has to review. Indeed, prior research by our team has found that the median duration of a case review by a MTB is 2 mins, which means that some patients are being "discussed" in an even shorter timeframe.[^10^](#cam43026-bib-0010){ref-type="ref"}, [^27^](#cam43026-bib-0027){ref-type="ref"}, [^28^](#cam43026-bib-0028){ref-type="ref"} Based on both our clinical and research experience, these very briefly reviewed cases would score low on MeDiC---that is, they represent the least complex patients. In healthcare systems such as the one of the UK, MeDiC offers the opportunity to consider screening of the highest scoring (ie, most complex) patients for full MTB review; and allowing the least complex patients to be managed according to well‐defined guidelines and standard pathways and ratified at the MTB.

Finally, in health systems where MTBs are not applied, MeDiC allows for a phased introduction of this approach, without overloading system resources: selecting patients according to how clinically and logistically complex they are, thus allowing such systems to experiment with setting up their cancer management pathways in a gradual manner---that is, by being selective regarding which patients they bring to the MTB\'s attention.

Based on our finding of variation in case complexity across tumor types, one MTB implementation design is unlikely to fit all situations[^26^](#cam43026-bib-0026){ref-type="ref"}. MTBs based at different centers that has different case mixes will have different requirements---for example, a tertiary referral cancer center will by definition deal with the most complex cases, either regionally or nationally. The MeDiC tool allows cancer centers to (re‐)design their care processes safely, with adequate governance in enabling patients to be streamlined through the MTB framework effectively. Regardless of how MeDiC is used, it is important that complex cases be reviewed at the beginning of a cancer conference, when teams are fresh, to prevent cognitive fatigue shown to impact decision‐making.[^27^](#cam43026-bib-0027){ref-type="ref"}, [^28^](#cam43026-bib-0028){ref-type="ref"}, [^29^](#cam43026-bib-0029){ref-type="ref"} Evidenced cognitive‐behavioral strategies should be implemented (eg, a short break mid‐meeting) if meetings are particularly long (\>1 hour) to prevent performance detriments.[^28^](#cam43026-bib-0028){ref-type="ref"}

This study has limitations. First, MeDiC was developed and tested within the UK\'s fully MTB‐driven cancer care system. Further testing is needed in other settings where tumor boards are not mandatory and information regarding the clinical complexity may be dispersed across systems and harder to assimilate. Second, MeDiC was tested in real time during MTBs. For most teams, however, the tool should be used to help with meeting preparation and streamlining.[^14^](#cam43026-bib-0014){ref-type="ref"}, [^26^](#cam43026-bib-0026){ref-type="ref"} The tool could be completed to generate a score when the decision to present a patient is made with subsequent case selection or ordering of cases on the MTB\'s agenda (to start with the most complex patients). Third, the expert review team consisted of predominantly surgeons and psychologists, hence insights from other specialists might be lacking. Nonetheless, all factors included in MeDiC were reviewed by a diverse national range of cancer specialists, thus adding credibility and validity to the tool.

Further research on MeDiC should explore how cut‐off scores could be established for each tumor or MTB type---we cannot assume that these will be uniform for all. Clinically, further sensitivity analyses need to be carried out, to ensure MeDiC does not miss complex patients in any way. From a cancer policy point of view, implementation of MeDiC and study of its impact on patient selection, efficiency and costs of care will allow health systems policy makers to determine how MTB‐driven care can be optimally implemented to enhance quality and efficiency in cancer care delivery.

5. CONCLUSION {#cam43026-sec-0021}
=============

MeDiC offers an evidence‐based and expert user‐informed tool that allows cancer teams and systems to select and/or streamline their patient caseload for optimal treatment planning and management.
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